CancerNetwork Members: Login | Register
 
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
PATIENTS
NURSES
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Ovarian Cancer

Oncology NEWS International. Vol. 19 No. 7
News & Analysis 

Some ovarian tumors can be safely followed on ultrasound

By REBEKAH MOAN | July 14, 2010
Once thought a risk for malignancy, septated ovarian cystic tumors are actually mostly benign. A study at the University of Kentucky changes the standard of care for those patients.

BROOK A. SAUNDERS, MD
BROOK A. SAUNDERS, MD

Certain complex ovarian tumors may be safely monitored using ultrasound without raising the risk of ovarian cancer, according to a study conducted at the University of Kentucky Markey Medical Center in Lexington. In the past, septated ovarian cystic tumors were deemed complex and the patients were sent immediately to surgery.

Brook A. Saunders, MD, and colleagues followed 29,829 women from 1987 to 2009 as part of the university's ovarian cancer screening program. Among the screened women, 1,319 had complex cystic ovarian tumors with septation. Provided there are no solid areas, or papillary projections evident on transvaginal sonography, these women do not require surgery, he said.




Ultrasound images of a single thin septated cyst (top); a single thick septated cyst (middle); and multiple septated cysts (bottom). Image courtesy of Edward J. Pavlik, director of research in gynecologic oncology, UK Ovarian Screening Research Program.

Dr. Saunders was a fellow at the university at the time of the study. His co-investigator was John R. van Nagell, Jr., MD, director of the division of gynecologic oncology.

"For septated cysts physicians used their clinical judgment but they could not guarantee they were benign," said Dr. Saunders, who is now a gynecologic oncologist at Knoxville Gynecologic Cancer Specialists in Knoxville, Tenn. "This study shows you still have to use your clinical judgment, but you have a much better idea these cysts are benign."

Asymptomatic women older than 50, or women 25 and older with a family history of ovarian cancer, came in for ovarian cancer screening once a year. If the ultrasound findings were abnormal the women came back for a transvaginal ultrasound in four to six weeks. If the cyst was considered simple, follow-up transvaginal ultrasound was conducted every three to six months. If the cyst was not considered simple—for instance it was septated—follow-up transvaginal ultrasound was conducted every four to six weeks.

In the 1,319 women with septated cystic ovarian tumors, 38.8% of the septated tumors resolved on their own. The researchers removed 128 septated tumors from the women but none were found to be malignant.

There were no statistical differences between the women who had tumors removed and those who did not. The only differences were the removal group had tumors greater than approximately 5 cm, and they had multiple septations, according to Dr. Saunders (2010 Society of Gynecologic Oncologists abstract 53).

"If the radiologist is seeing a septated cyst, it is more than likely a benign septated cyst as long as there are no papillary areas or solid areas," Dr. Saunders said. "If you have a good ultrasound where you can see that, you can reliably relay that information to the clinician who ordered the test."

VANTAGE POINT
SUSAN MODESITT, MD
SUSAN MODESITT, MD
Reiterating the low risk of malignancy for postmenopausal masses

The University of Kentucky study provides strong evidence due to the large cohort and extended follow up, said Dr. Modesitt, division director of gynecologic oncology at the University of Virginia School of Medicine in Charlottesville.

"I remember when I was a medical student, or a resident, if any post-menopausal mass was detected it was felt it needed to be removed because of the risk of malignancy," she said. "However, in the intervening years, we've discovered, largely through screening programs like the one at the University of Kentucky, that many of these can be observed, and they have very low risk of malignancy."

The current study by Dr. Saunders and colleagues reinforces that finding, she said.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by Sue Mocnik | August 11, 2010 11:45 AM EDT

this is wonderful news!






 
RELATED CONTENT

A Step Forward Toward Better Characterization of Ovarian Cancer
January 19, 2012
46-Year-Old Woman Presents With Difficulty in Ambulation, and Swelling and Discoloration of Both Eyelids
ONCOLOGY,  January 9, 2012
Small Study Shows Promise of a Vaccine for Metastatic Breast and Ovarian Cancer
November 10, 2011
Counseling Women at High Risk of Ovarian or Endometrial Cancer
ONCOLOGY Nurse Edition,  October 19, 2011
HE4 Biomarker Test Is Approved for Use in Risk of Ovarian Malignancy Algorithm (ROMA)
ONCOLOGY Nurse Edition,  October 18, 2011
 
TOPIC INDEX

  • Bladder Cancer
  • Bone Metastases
  • Breast Cancer
  • CML
  • Colorectal Cancer
  • End-of-Life
  • GIST
  • Genetics Genomics
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Integrative Oncology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Nausea & Vomiting
  • Palliative Care
  • Pancreatic Cancer
  • Practice Management
  • Practice & Policy
  • Prostate Cancer
  • RCC
  • Skin Cancer
  • Triple-Negative Breast
  • Testicular Cancer


More Topics 


 
Journal Content
 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Tax Schemes Every Physician Should Avoid
Ike Devji, JD, January 31, 2012
The next 60 days marks the final push to sell physicians across the United States tax plans of both good and questionable value.
Boosting Collections at Your Medical Practice: Whose Job Is It?
P.J. Cloud-Moulds, January 28, 2012
Embrace the relationship between your billing company and your medical practice staff.
Managing Difficult Medical Practice Employees
Shelly K. Schwartz, January 27, 2012
Tips for transforming immature staff members into great employees.
Prevent Physician Distraction When Using mHealth Technology
Aubrey Westgate, January 25, 2012
As more and more physicians use handheld mobile technology in their day-to-day work, some critics are raising concerns about “distracted doctoring.”
Can That Applicant Do the Job at Your Medical Practice?
Karen Zupko, January 25, 2012
If like many communities, yours has significant numbers of non-English speaking people with whom neither you nor your staff are able to converse, your practice is at a serious disadvantage.
 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Head and Neck Tumors
  • 46-Year-Old Woman Presents With Difficulty in Ambulation, and Swelling and Discoloration of Both Eyelids
  • Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
  • A 28-Year-Old Woman Presents With a Long-Standing History of Intermittently Painful “Bumps” on Both Her Shoulders and Upper Back
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Evolution of Treatment Options for Patients With CRPC and Bone Metastases: Bone-Targeted Agents That Go Beyond Palliation of Symptoms to Improve Overall Survival
  • Ending the Shortage of Generic Oncology Drugs
  • Processed and Red Meat Consumption Linked to Slight Increase in Risk of Pancreatic Cancer
  • New Mutation May Act as Driver in Subset of Lung Cancer Patients
  • Could Aspirin Be a Viable Adjuvant Treatment for Cancer?
  • Advances and New Research in the Treatment of Kidney Cancer
  • New Way to Predict Prostate Cancer Severity—Size of Prostate
  • Vismodegib Granted FDA Approval for Treatment of Basal Cell Carcinoma
  • FDA Grants Approval to Axitinib for the Treatment of Advanced Renal Cell Carcinoma
  • Why BRAF-Mutated Colorectal Cancers Don't Respond to BRAF Inhibitors
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • When to Treat Myelodysplastic Syndromes
  • Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?
  • Evolving Therapeutic Paradigms for Advanced Prostate Cancer
Click here to subscribe to our newsletter
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs


CancerNetwork on Facebook

 

 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Ovarian Cancer
Evidence on Ovarian Cancer
Guidelines on Ovarian Cancer
Patient Education on Ovarian Cancer
Clinical Trials on Ovarian Cancer
Practical Articles on Ovarian Cancer
Research and Reviews on Ovarian Cancer
All "Ovarian Cancer" results

CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy